US5571817AExpiredUtility

Methods of treating androgenic alopecia with finasteride [17β-N-mono-substituted-carbamoyl-4-aza-5-α-androst-1-en-ones]

73
Assignee: MERCK & CO INCPriority: Feb 27, 1984Filed: Jul 20, 1993Granted: Nov 5, 1996
Est. expiryFeb 27, 2004(expired)· nominal 20-yr term from priority
C07J 73/005C07C 62/38C07C 2603/16A61K 31/58
73
PatentIndex Score
18
Cited by
150
References
2
Claims

Abstract

17 beta -N-monosubstituted-carbamoyl-4-5 alpha -androst-1-en-3-ones of the formula <IMAGE> I wherein R1 is selected from hydrogen, methyl and ethyl and R2 is a branched chain alkyl of from 3-12 carbons, and R', R'', R''' are hydrogen or methyl are active as testosterone 5 alpha -reductase inhibitors and thus are useful topically for treatment of androgenic alopecia.

Claims

exact text as granted — not AI-modified
What is claimed is: 
     
       1. A method of treating androgenic alopecia which comprises orally administering to a human in need of such treatment a therapeutically effective amount of 17β-(N-tert-butylcarbamoyl)-4-aza-5α-androst-1-en-3-one. 
     
     
       2. The method of claim 1 wherein the androgenic alopecia is male pattern alopecia.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.